Prognostic factors for lung function in systemic sclerosis: Prospective study of 105 cases

European Respiratory Journal

Volumn 35, Issue 1, 2010, Pages 112-117

  Gilson, M ^a   Zerkak, D ^a   Wipff, J ^a   Dusser, D ^a   Dinh Xuan, A T ^a   Abitbol, V ^a   Chaussade, S ^a   Legmann, P ^a   Kahan, A ^a   Allanore, Y ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Diffuse scleroderma; Gastro oesophageal reflux; Interstitial lung disease; Oesophageal manometry; Prognostic factors; Systemic sclerosis

Indexed keywords

CARBON MONOXIDE; CYCLOPHOSPHAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROKINETIC AGENT; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; CARBON MONOXIDE BLOOD LEVEL; COHORT ANALYSIS; DISEASE DURATION; ESOPHAGUS FUNCTION DISORDER; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; INTERSTITIAL LUNG DISEASE; LONGITUDINAL STUDY; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MANOMETRY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SYSTEMIC SCLEROSIS;

ESOPHAGEAL DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC;

EID: 75149159773     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00060209     Document Type: Article

References (28)

1. Schurawitzki H, Stiglbauer R, Graninger W, et al. Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography. Radiology 1990; 176: 755-759.
2. Steen VD, Conte C, Owens GR, et al. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37: 1283-1289.
3. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940-944.
4. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am 2003; 29: 239-254.
5. Allanore Y, Avouac J, Wipff J, et al. New therapeutic strategies in the management of systemic sclerosis. Expert Opin Pharmacother 2007; 8: 607-615.
6. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-2666.
7. Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176: 1026-1034.
8. Tobin RW, Pope CE 2nd, Pellegrini CA, et al. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158: 1804-1808.
9. Schachter LM, Dixon J, Pierce RJ, et al. Severe gastroesophageal reflux is associated with reduced carbon monoxide diffusing capacity. Chest 2003; 123: 1932-1938.
10. Lock G, Pfeifer M, Straub RH, et al. Association of esophageal dysfunction and pulmonary function impairment in systemic sclerosis. Am J Gastroenterol 1998; 93: 341-345.
11. Marie I, Dominique S, Levesque H, et al. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 2001; 45: 346-354.
12. Savarino E, Bazzica M, Zentilin P, et al. Gastro-esophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med 2009; 179: 408-413.
13. Troshinsky MB, Kane GC, Varga J, et al. Pulmonary function and gastroesophageal reflux in systemic sclerosis. Ann Intern Med 1994; 121: 6-10.
14. Wipff J, Allanore Y, Soussi F, et al. Prevalence of Barrett's esophagus in systemic sclerosis. Arthritis Rheum 2005; 52: 2882-2888.
15. Medsger TA Jr. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am 2003; 29: 255-273.
16. Hurwitz AL, Duranceau A, Postlethwait RW. Esophageal dysfunction and Raynaud's phenomenon in patients with scleroderma. Am J Dig Dis 1976; 21: 601-606.
17. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005; 118: 2-10.
18. Wells AU, Hansell DM, Rubens MB, et al. Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings in relation to computed tomographic appearance. Am J Respir Crit Care Med 1994; 150: 462-468.
19. Goldin JG, Lynch DA, Strollo DC, et al. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest 2008; 134: 358-367.
20. Lock G, Holstege A, Lang B, et al. Gastrointestinal manifestations of progressive systemic sclerosis. Am J Gastroenterol 1997; 92: 763-771.
21. de Souza RB, Borges CT, Capelozzi VL, et al. Centrilobular fibrosis: an underrecognized pattern in systemic sclerosis. Respiration 2009; 77: 389-397.
22. Limburg AJ, Beekhuis H, Smit AJ, et al. Esophageal hypomotility in primary and secondary Raynaud's phenomenon: comparison of esophageal scintigraphy with manometry. J Nucl Med 1995; 36: 451-455.
23. Bassotti G, Battaglia E, Debernardi V, et al. Esophageal dysfunction in scleroderma: relationship with disease subsets. Arthritis Rheum 1997; 40: 2252-2259.
24. Yarze JC, Varga J, Stampfl D, et al. Esophageal function in systemic sclerosis: a prospective evaluation of motility and acid reflux in 36 patients. Am J Gastroenterol 1993; 88: 870-876. 25 Richter JE. Oesophageal motility disorders. Lancet 2001; 358: 823-828.
25. Ebina M, Shimizukawa M, Shibata N, et al. Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004; 169: 1203-1208.
26. Clements PJ, Roth MD, Elashoff R, et al. Scleroderma Lung Study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis 2007; 66: 1641-1647.
27. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248-1254.
28. Marie I, Ducrotte P, Denis P, et al. Oesophageal mucosal involvement in patients with systemic sclerosis receiving proton pump inhibitor therapy. Aliment Pharmacol Ther 2006; 24: 1593-1601.